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Introduction: Serological testing is needed to better understand the epidemiology of the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Rapid diagnostic tests (RDTs) have been devel- 
oped to detect specific antibodies, IgM and IgG, to the virus. The performance of 25 of these RDTs was 
evaluated. 
Methods: A serological reference panel of 50 positive and 100 negative plasma specimens was developed 
from SARS-CoV-2 PCR and antibody positive patients and pre-pandemic SARS-CoV-2-negative specimens 
collected in 2016. Test performance of the 25 RDTs was evaluated against this panel. 
Results: A total of 10 RDTs had a sensitivity ≥98%, while 13 RDTs had a specificity ≥98% to anti-SARS- 
CoV-2 IgG antibodies. Four RDTs (Boson, MultiG, Standard Q, and VivaDiag) had both sensitivity and 
specificity ≥98% to anti-SARS-CoV-2 IgG antibodies. Only three RDTs had a sensitivity ≥98%, while 10 
RDTs had a specificity ≥98% to anti-SARS-CoV-2 IgM antibodies. Three RDTs (Autobio, MultiG, and Stan- 
dard Q) had sensitivity and specificity ≥98% to combined IgG/IgM. The RDTs that performed well also 
had perfect or almost perfect inter-reader agreement. 
Conclusions: This evaluation identified three RDTs with a sensitivity and specificity to IgM/IgG antibodies 
of ≥98% with the potential for widespread antibody testing in Uganda. 
Crown Copyright © 2021 Published by Elsevier Ltd on behalf of International Society for Infectious 
Diseases. 

















Coronavirus disease 2019 (COVID-19) was declared a pandemic 
y the World Health Organization (WHO) on March 11, 2020. Glob- 
lly as of September 1, 2021, there have been nearly 218 million 
ases reported to the WHO with over 4.5 million deaths, while in 
ganda 99 408 cases with over 30 0 0 deaths have been recorded ∗ Corresponding author: Pontiano Kaleebu, Uganda Virus Research Institute, Plot 
1–59, Nakiwogo Road, PO Box 49, Entebbe, Uganda. 






201-9712/Crown Copyright © 2021 Published by Elsevier Ltd on behalf of International S
icense ( http://creativecommons.org/licenses/by/4.0/ )  WHO, 2021 ). Since this evaluation, the number of new cases and 
eaths has continued to rise. 
Standard laboratory confirmation of severe acute respiratory 
yndrome coronavirus 2 (SARS-CoV-2) is based on the detection of 
nique viral sequences in nasopharyngeal samples by nucleic acid 
mplification test (NAAT) ( WHO, 2020b ). Although the priority in- 
ervention from a public health perspective has been to identify 
hose with acute infection and to quarantine them and their im- 
ediate contacts in order to control the spread of infection, it has 
ecome apparent that it is also important to identify convalescent 
ases through antibody testing in order to better understand the ociety for Infectious Diseases. This is an open access article under the CC BY 


















































































































pidemiology of the virus and thereby to introduce effective con- 
rol measures. Antibody testing has traditionally been conducted 
sing enzyme-linked immunosorbent assays (ELISAs) or more re- 
ently with rapid diagnostic tests (RDTs). ELISAs facilitate the test- 
ng of large numbers of specimens per run, while RDTs are lateral 
ow devices for individual specimens. RDTs typically give results 
n less than 30 minutes and are therefore ideal for use at the point
f care (POC). During the early days of the pandemic, commercial 
LISAs and RDTs were hard to come by and none were approved 
or use in Uganda. 
Most people infected with SARS-CoV-2 have an incubation pe- 
iod of 3–7 days before the appearance of symptoms. IgM serocon- 
ersion occurs within 10–14 days and IgG seroconversion within 
2–14 days after symptom onset ( Long et al., 2020 ; Lou et al.,
020 ; To et al., 2020 ; Zhao et al., 2020 ) and can be detected in
ess than 40% of infected people within 1 week of symptom on- 
et and in 100% by day 15 ( Batra et al., 2020 ; Zhao et al., 2020 ).
ntibodies can take much longer to develop in those with a sub- 
linical or mild infection ( WHO, 2020b ). The strength of the anti- 
ody response depends on a number of factors including age, nu- 
ritional status, and disease severity amongst others ( WHO, 2020a ). 
gM antibodies start to disappear by week 5, and by week 7 they 
re no longer detectable; IgG antibodies persist beyond week 7 
 Xiao et al., 2020 ). It is not clear whether antibodies confer im-
unity to re-infection, although the recurrence of COVID-19 illness 
ppears to be very uncommon ( CDC, 2020a ). 
As a result of global shortages of reagents for molecular testing, 
 number of groups ( Lassaunière et al., 2020 ; Zhao et al., 2020 )
ave investigated the potential use of antibody tests, particularly 
hose for IgM, either singly or in combination, to diagnose acute 
ARS-CoV-2 infection. However, a reliable diagnosis of infection by 
ntibody testing is only possible in the recovery phase when the 
ossibility of intervening has passed and consequently serological 
iagnosis is not recommended for informing clinical management 
r contact-tracing ( WHO, 2020b ). 
In Uganda, as in many other countries, there is a sense of ur- 
ency to understand the epidemiology of the virus in order to 
mplement effective control measures. This requires mass screen- 
ng of the population for anti-SARS-CoV-2 antibodies to determine 
mong other things: how many people have been infected with 
he virus and how this changes over time; the risk factors for in- 
ection such as age, ethnicity, domicile, or underlying health is- 
ues; the proportion of infected people with mild or asymptomatic 
nfection and how long antibodies can be detected in individuals 
ho have been infected ( CDC, 2021 ). Many countries are now test- 
ng for SARS-CoV-2 antibodies at the population level or in specific 
roups, such as health workers, close contacts of known cases, or 
ithin households ( WHO, 2020c ). 
The tools to conduct mass serological screening, including ELISA 
nd RDT kits with emergency use approval, slowly became avail- 
ble in mid-2020 and plans were made to evaluate their perfor- 
ance. 
Laboratory tests including RDTs that detect antibodies to SARS- 
oV-2 in people need validation to determine their accuracy and 
eliability. Inaccurate RDT results would have serious consequences 
nd would affect pandemic control effort s. In Uganda, all new diag- 
ostic assays that are introduced into the market must undergo in- 
ountry laboratory validation at the Uganda Virus Research Insti- 
ute (UVRI), which is a designated WHO and Africa Centres for Dis- 
ase Control and Prevention (CDC) SARS-CoV-2 reference labora- 
ory, before being recommended to the Ministry of Health for use 
n the country. Both the US Centers for Disease Control and Pre- 
ention, and WHO also advise that diagnostic and antibody tests 
hould be validated in appropriate populations and settings before 
hey are recommended ( CDC, 2020b ; WHO, 2017 ). c
282 For this evaluation, ELISAs and chemiluminescent microparticle 
mmunoassays (CMIA) with one or more approvals under the US 
ood and Drug Administration (FDA), Emergency Use Authoriza- 
ion (EUA) or the WHO Emergency Use Listing (EUL), or with the 
uropean Conformité Européenne (CE) mark were procured (sup- 
lementary files, Appendix A). For the rapid tests, local distribu- 
ors provided 25 serological RDTs for a cost-free evaluation at the 
VRI (supplementary files, Appendix B). Nine distributors provided 
nough test kits for the evaluation of 150 samples, while 16 dis- 
ributors provided test kits for less than 150 samples (73–125). 
. Materials and methods 
.1. Serological reference panel 
At UVRI, the normal practice to validate new antibody test 
its is to evaluate their performance on a reference panel of 
ell-characterized plasma specimens. In mid-2020, no commercial 
r WHO reference panels were available and consequently UVRI 
eveloped its own reference panel. Presumptive anti-SARS-CoV-2 
ntibody-positive specimens were selected from available qRT-PCR- 
onfirmed, symptomatic and asymptomatic SARS-CoV-2 cases; the 
umber of days post symptom onset was reported for some of 
he symptomatic cases. Presumptive SARS-CoV-2 antibody-negative 
pecimens were selected from the UVRI repository of specimens 
ollected during an HIV national serosurvey conducted in 2016, 
ong before the COVID-19 pandemic. 
Specimens from qRT-PCR-confirmed SARS-CoV-2-positive cases 
ere tested using the following six assays in accordance with 
he manufacturers’ ‘information for use’ (IFU) instructions: (1) Ar- 
hitect SARS-CoV-2 IgG CMIA (nucleocapsid protein); (2) Archi- 
ect SARS-CoV-2 IgM CMIA (spike protein); (3) Euroimmun Anti- 
ARS-CoV-2 ELISA (IgG) (spike protein); (4) EDI Novel Coronavirus 
OVID-19 IgG ELISA (nucleocapsid protein); (5) EDI Novel Coron- 
virus COVID-19 IgM ELISA (nucleocapsid protein); (6) InBios SCoV- 
 Detect IgM ELISA (spike protein). A positive sample was defined 
s a sample reactive on at least two IgG ELISA/CMIA targeting the 
pike protein (Euroimmun Anti-SARS CoV-2 ELISA-IgG) and the nu- 
leocapsid protein (Architect SARS-CoV-2 IgG CMIA) and also reac- 
ive on at least two IgM ELISA/CMIA targeting the spike protein 
InBios SCoV-2 Detect IgM ELISA and Architect SARS-CoV-2 IgM 
MIA). The EDI Novel Coronavirus COVID-19 IgG and IgM ELISA had 
ow sensitivity and hence results with these assays were not con- 
idered during the selection of specimens for the positive panel. 
Fifty samples with the above profile were included in the SARS- 
oV-2-positive reference panel ( UVRI, 2021 ). 
SARS-CoV-2-(presumed) negative specimens were tested using 
he following four assays in accordance with the manufacturers’ 
FUs: (1) InBios-SCoV-2 Detect IgM ELISA (spike protein); (2) Eu- 
oimmun Anti-SARS CoV-2 ELISA-IgG (spike protein); (3) Archi- 
ect SARS CoV2-IgG CMIA (nucleocapsid protein); (4) SD Biosen- 
or Standard E COVID-19 Total Ab ELISA (spike protein). A negative 
ample was defined as a sample that was non-reactive in at least 
hree of the four assays. 
One hundred samples with the above profile were included in 
he SARS-CoV-2-negative reference panel ( UVRI, 2021 ). 
.2. Rapid diagnostic tests 
A total of 25 serological RDTs (Appendix B) were evaluated 
gainst the characterized serological reference panel. The anti- 
en(s), spike and/or nucleocapsid protein, targeted by the RDTs was 
ot disclosed in the IFUs for most of the RDTs. The majority of 
DTs had a single reading window with a control line, an IgM test 
ine, and an IgG test line, while one (Biocredit) had two separate 
assettes. Two RDTs had a reading window for IgM/IgG (Sino Care 








































































































nd Wondfo), while one had reading windows for IgG and IgA/IgM 
nd not IgM (Antai). The manufacturers’ IFUs were followed and 
he results were read by two technicians blinded to each other’s 
esults. 
.3. Statistical analysis 
The statistician conducting the data analysis was blinded to the 
DT identity. Only concordant results between technicians were 
sed to evaluate the performance of the RDTs; inter-reader vari- 
bility was also documented. 
.3.1. Sensitivity 
The sensitivity was calculated as the number of specimens de- 
ermined as positive by the two technicians for each RDT under 
valuation, divided by the number of specimens tested from the 
ositive panel; this was expressed as a percentage. 
.3.2. Specificity 
The specificity was calculated as the number of specimens de- 
ermined as negative by the two technicians for each RDT under 
valuation, divided by the number of specimens tested from the 
egative panel; this was expressed as a percentage. 
.3.3. Accuracy 
The accuracy was calculated as the proportion of RDT test re- 
ults that agreed with the panel source (positive and negative pan- 
ls) and was expressed as a percentage. The sensitivity, specificity, 
nd accuracy calculations were performed using the proportion 
ommand in STATA 15 and confidence intervals (CI) were produced 
ith the Wilson score method ( Newcombe, 1998 ). 
Sensitivity, specificity, and accuracy were also determined for 
ombined IgM/IgG (either or both IgM and IgG). 
.3.4. Inter-reader agreement 
The observed proportion and level of agreement between the 
wo technicians were examined using the Cohen’s kappa statis- 
ic. This was generated for each isotype (IgM and IgG) of each 
DT evaluated. The level of agreement was categorized as fol- 
ows: no agreement ( < 0), slight agreement (0.0–0.20), fair agree- 
ent (0.21–0.40), moderate agreement (0.41–0.60), substantial 
greement (0.61–0.80), and almost perfect agreement (0.81–1.00) 
 McHugh, 2012 ). 
.4. Ethical considerations 
The evaluation protocol was reviewed and approved by the Re- 
earch Ethics Committee of the UVRI and the Uganda National 
ouncil for Science and Technology (UNCST). The panels were un- 
inked to personal identifiers and the results could not be traced 
o individual patients. Consent to participate and to store samples 
or future use was also sought. 
. Results 
.1. Performance 
Results by individual RDT performance are summarized (in al- 
habetical order) in Table 1 . Most RDTs showed poor performance, 
ith none showing both anti-SARS-CoV-2 IgM and IgG antibody 
ensitivity and specificity ≥98%. Many RDTs that performed well in 
t least one reading window showed good reactivity to anti-SARS- 
oV-2 IgG antibodies, with 10 having a sensitivity ≥98%, while 13 
ad a specificity ≥98% ( Table 1 ). Only three RDTs had an anti-
ARS-CoV-2 IgM antibody sensitivity ≥98%, while 10 RDTs had a 
pecificity ≥98% for anti-SARS-CoV-2 IgM antibodies. Three RDTs 283 Autobio, MultiG, and Standard Q) had a sensitivity and a speci- 
city ≥98% to combined IgM/IgG. There were seven RDTs that had 
n accuracy ≥98% for anti-SARS-CoV-2 IgG antibodies, with three 
Boson, Standard Q, and VivaDiag) having an accuracy of 100%. 
here were four RDTs (Boson, MultiG, Standard Q, and VivaDiag) 
here both anti-SARS-CoV-2 IgG antibody sensitivities and speci- 
cities were ≥98%. 
.2. Inter-reader agreement 
There was almost perfect agreement between the two techni- 
ians for the determination of IgG in 20/23 RDTs (87.0%) (where 
here was a reading window for IgG). Four of the RDTs had perfect 
greement for IgG, with a kappa statistic of 100% (Biocredit, BTNX, 
ultiG, Standard Q, and VivaDiag). Agreement in determining IgM 
as much lower, with only 11/23 tests (47.8%) where there was 
lmost perfect agreement ( Table 2 ). 
. Discussion 
The WHO continues to review the evidence on antibody re- 
ponses to SARS-CoV-2 infection and has published guidance on 
djusting public health and social measures for the next phase of 
he COVID-19 response ( WHO, 2019 ). The development of accurate 
DTs for the diagnosis of anti-SARS-CoV-2 IgM and IgG antibodies 
ill benefit epidemiological and surveillance studies in identifying 
ast COVID-19 symptomatic and asymptomatic infections including 
hose in ‘hot-spots’. This will serve as an aid in determining the ex- 
ent of herd immunity, although for how long immunity will last, 
specially with the appearance of SARS-CoV-2 variants, is not yet 
nown ( Aschwanden, 2021 ). Accurate RDTs detecting the relevant 
ntibodies will benefit vaccine studies in identifying SARS-CoV-2 
accine responders and for how long one remains immune to the 
irus. 
This evaluation of 25 RDTs showed significant variation in per- 
ormance, emphasizing the need for more input in research and 
evelopment in order to come up with more accurate tests. There 
ere only four RDTs that had a sensitivity and specificity ≥98% for 
nti-SARS-CoV-2 IgG, i.e., Boson, MultiG, Standard Q, and VivaDiag. 
f these four RDTs, only Boson had a sensitivity ≥98% for anti- 
ARS-CoV-2 IgM (sensitivity was 100% and corresponding speci- 
city was 87.0% for anti-SARS-CoV-2 IgM; Table 1 ). When com- 
ining IgM and IgG, this evaluation identified three RDTs (Autobio, 
ultiG, and Standard Q) with a sensitivity and specificity ≥98% for 
oth IgG and/or IgM. 
There was better agreement between the two technicians for 
esult determination of IgG compared to result determination of 
gM, with 87.0% having almost perfect agreement for IgG compared 
o only 47.8% for IgM. Five of the RDTs had perfect agreement for 
gG, with a kappa statistic of 100% (Biocredit, BTNX, MultiG, Stan- 
ard Q, VivaDiag), while there was no such finding for IgM. 
Combination IgG/IgM RDTs can provide unclear results given 
he po tential for cross-reactivity of antibodies with other coro- 
aviruses and the often poor specificity of IgM serological assays 
 IDSA, 2020 ). The use of some of these combination IgG/IgM RDTs 
ay not be simple to interpret in the field if only the IgG test com-
onent of the RDT gives accurate results. Some RDTs had one cas- 
ette with separate IgM and IgG bands, while others had separate 
assettes for IgG and IgM. If one used an RDT with a cassette hav- 
ng both IgM and IgG and with IgM having poor specificity, then 
he final result describing past exposure may be confusing and in- 
ccurate, unless the reader disregards the IgM results altogether. 
For the above reasons, it may be more practical to recommend 
he use of RDTs with both a sensitivity and specificity of ≥98% for 
gM and IgG combined; Autobio, MultiG, and Standard Q fit this 
rofile. 
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Table 1 
Field performance (sensitivity, specificity, and accuracy) of 25 rapid diagnostic tests (RDTs) evaluated at UVRI. 
RDT Number evaluated Isotype Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI) 
Abbott Panbio 150 IgM 66.2 (57.6–73.8) 90.3 (82.2–94.9) 66.2 (57.6–73.8) 
IgG 98.5 (94.3–99.6) 97.7 (91.0–99.4) 98.5 (94.3–99.6) 
IgM/IgG 92.0 (86.9–95.8) 88.7 (6.3–19.5) 92.0 (86.9–95.8) 
Absoludy 100 IgM 16.3 (8.2–30.0) 100 (92.9–100) 58.6 (48.5–68.0) 
IgG 95.9 (84.4–99.0) 98.0 (86.3–99.7) 97.0 (90.9–99.0) 
IgM/IgG 96.0 (84.7–99.0) 98.0 (86.3–99.7) 97.0 (90.9–99.0) 
Antai 73 IgG 10 (2.2–35.5) 94.6 (79.7–98.7) 50.7 (39.1–62.2) 
IgG/IgM 16.7 (3.3–54.3) 94.6 (79.7–98.7) 50.7 (39.1–62.2) 
IgG/IgA/IgM 37.9 (21.6–57.6) 79.5 (64.5–89.3) 63.0 (51.2–73.5) 
Autobio 100 IgM 37.8 (23.3–55.0) 100 (92.7–100) 73.6 (63.1–81.9) 
IgG 98 (86.3–99.7) 97.8 (85.2–99.7) 97.9 (91.9–99.5) 
IgM/IgG 100 (92.9–100) 98.0 (86.3–99.7) 99.0 (93.0–99.9) 
Biocredit 100 IgM 4.2 (1.0–15.9) 98 (86.3–99.7) 52.0 (42.0–61.9) 
IgG 2.0 (0.3–13.7) 100 (92.9–100) 51.0 (41.1–60.8) 
IgM/IgG 4.0 (1.0–15.3) 98.0 (86.3–99.7) 51.0 (41.1–60.8) 
BioSpeedia 150 IgM 100 (92.9–100) 10.5 (5.5–19.1) 43.4 (35.2–51.9) 
IgG 100 (92.9–100) 81.9 (72.6–88.6) 88.2 (81.7–92.6) 
IgM/IgG 100 (92.9–100) 20.0 (13.2–29.2) 46.7 (38.7–54.8) 
BTNX 125 IgM 89.8 (77.1–95.8) 97.3 (89.7–99.4) 94.4 (88.5–97.3) 
IgG 96.0 (84.7–99.0) 100 (95.1–100) 98.4 (93.7–99.6) 
IgM/IgG 100 (92.9–100) 97.3 (89.7–99.4) 98.4 (93.7–99.6) 
Boson 100 IgM 100 (92.7–100) 87.0 (73.2–94.2) 93.7 (86.5–97.2) 
IgG 100 (93.9–100) 100 (92.6–100) 100 (96.2–100) 
IgM/IgG 100 (92.9–100) 87.8 (74.2–94.6) 93.9 (87.0–97.3) 
Cellex–q 150 IgM 73.8 (57.9–85.2) 88.2 (79.7–93.4) 83.7 (76.4–89.1) 
IgG 96.0 (84.7–99.0) 98.0 (92.0–99.5) 97.3 (92.9–99.0) 
IgM/IgG 96.0 (84.7–99.0) 87.9 (79.7–93.1) 90.6 (84.7–94.4) 
CoronaCHEK 148 IgM 81.1 (64.4–91.0) 100 (96.2–100) 94.7 (89.3–97.5) 
IgG 60.5 (44.7–74.3) 100 (96.2–100) 87.9 (81.4–92.4) 
IgM/IgG 83.0 (68.9–91.5) 100 (96.2–100) 94.5 (89.3–97.2) 
Egens 100 IgM 59.6 (44.6–73.0) 93.3 (80.6–97.9) 76.1 (66.1–83.8) 
IgG 68.8 (53.9–80.6) 98.0 (86.0–99.7) 83.5 (74.6–89.7) 
IgM/IgG 69.4 (54.7–81.0) 94.0 (82.4–98.1) 81.8 (72.8–88.3) 
Hightop 119 IgM 19.5 (9.8–35.2) 98.6 (90.0–99.8) 69.1 (59.7–77.1) 
IgG 76.6 (61.9–86.8) 98.6 (90.0–99.8) 89.7 (82.5–94.1) 
IgM/IgG 72.0 (57.6–83.0) 97.1 (88.8–99.3) 86.8 (79.0–91.7) 
MultiG 100 IgM 22.4 (12.6–36.7) 98.0 (86.3–99.7) 61.6 (51.5–70.8) 
IgG 100 (92.9–100) 98.0 (86.3–99.7) 99.0 (93.0–99.9) 
IgM/IgG 100 (92.9–100) 98.0 (86.3–99.7) 99.0 (93.0–99.9) 
Novita 150 IgM 17.4 (8.7–31.7) 100 (96.3–100) 74.0 (66.2–80.5) 
IgG 40 (25.6–56.4) 100 (96.3–100) 82.9 (75.9–88.3) 
IgM/IgG 40 (27.1–54.5) 100 (96.3–100) 80.0 (72.7–85.7) 
Orient Gene 150 IgM 80.9 (66.5–90.0) 95.3 (89.2–98.5) 90.9 (84.9–94.7) 
IgG 98.0 (86.3–99.7) 95.9 (89.5–98.5) 96.6 (92.1–98.6) 
IgM/IgG 98.0 (86.3–99.7) 93.9 (87.0–97.3) 95.3 (90.4–97.8) 
Really Take 100 IgM 93.5 (80.9–98.0) 100 (92.9–100) 93 (85.9–96.7) 
IgG 97.9 (85.5–99.7) 96 (84.7–99.0) 94 (87.1–97.3) 
IgM/IgG 93.5 (80.9–98.0) 100 (92.9–100) 96.9 (90.6–99.0) 
Shanghai Liangrun 119 IgM 0 (0–7.3) 100 (94.7–100) 58.5 (49.3–67.1) 
IgG 93.8 (81.7–98.1) 94.1 (85.0–97.8) 94.0 (87.8–97.1) 
IgM/IgG 91.8 (79.6–97.0) 94.2 (85.2–97.9) 93.2 (86.9–96.6) 
Sino Care 100 IgM NA ∗ NA NA 
IgG NA NA NA 
IgM/IgG 47.9 (33.8–62.3) 92 (80.0–97.1) 69 (59.1–77.4) 
Standard Q 100 IgM 95.9 (84.4–99.0) 98.0 (86.3–99.7) 97.0 (90.9–99.0) 
IgG 100 (92.9–100 100 (92.9–100) 100 (96.3–100) 
IgM/IgG 100 (92.9–100) 98.0 (86.3–99.7) 99.0 (93.0–99.9) 
Tigsun 150 IgM 36.2 (23.4–51.2) 77.5 (67.5–85.1) 63.2 (54.7–71.0) 
IgG 80.9 (66.5–90.0) 90.3 (82.2–94.9) 87.1 (80.4–91.8) 
IgM/IgG 79.6 (65.5–88.9) 73.5 (63.7–81.4) 75.5 (67.8–81.9) 
Vazyme 100 IgM 14.3 (6.8–27.6) 81.3 (67.1–90.2) 47.4 (37.5–57.5) 
IgG 100 (92.9–100) 95.9 (84.4–99.0) 98.0 (92.1–99.5) 
IgM/IgG 100 (92.9–100) 80.0 (66.1–89.1) 90.0 (82.2–94.6) 
VivaDiag 150 IgM 93.8 (81.7–98.1) 97.0 (90.9–99.0) 95.9 (91.1–98.2) 
IgG 100 (92.9–100) 100 (96.3–100) 100 (97.5–100) 
IgM/IgG 100 (92.9–100) 97.0 (90.9–99.0) 98.0 (93.9–99.4) 
Wiz Biotech 150 IgM 98.0 (86.0–99.7) 0 (0–3.7) 32.2 (25.1–40.2) 
IgG 98.0 (86.0–99.7) 0 (0–3.7) 32.2 (25.1–40.2) 
IgM/IgG 98.0 (86.0–99.7) 0 (0–3.7) 32.2 (25.1–40.2) 
Wondfo 100 IgM NA a NA NA 
IgG NA NA NA 
IgM/IgG 95.8 (84.1–99.0) 98 (86.3–99.7) 96.9 (90.8–99.0) 
( continued on next page ) 
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Table 1 ( continued ) 
RDT Number evaluated Isotype Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI) 
Zybio 100 IgM 93.6 (81.3–98.0) 79.5 (64.5–89.3) 86.8 (78.0–92.4) 
IgG 95.9 (84.4–99.0) 100 (92.6–100) 97.9 (91.9–99.5) 
IgM/IgG 96.0 (84.7–99.0) 81.6 (67.7–90.4) 88.9 (80.9–93.8) 
CI, confidence interval; UVRI, Uganda Virus Research Institute. 
a NA indicates that the sensitivity and specificity of these tests could not be generated separately because the 
kits did not have separate reading windows for IgM and IgG. 
Table 2 
The observed proportion of agreement and Cohen’s kappa statistic for the 25 rapid diagnostic tests (RDTs) 
RDT Number of kits received for evaluation Isotype Observed proportion of agreement (%) Kappa 
Abbott 
Panbio 
150 IgM 88.7 0.55 
IgG 91.3 0.82 
Absoludy 100 IgM 99.0 0.94 
IgG 99.0 0.98 
Antai 73 IgG 78.1 0.25 
IgG/IgM 67.1 0.15 
Autobio 100 IgM 87.0 0.61 
IgG 96.0 0.92 
Biocredit 100 IgM 98.0 0.74 
IgG 100 1.0 
BioSpeedia 150 IgM 90.7 0.52 
IgG 96.0 0.92 
BTNX 125 IgM 99.2 0.98 
IgG 100 1.0 
Boson 100 IgM 95.0 0.90 
IgG 98.0 0.96 
Cellex- 
q 
150 IgM 90.0 0.77 
IgG 98.7 0.97 
CoronaCHEK 148 IgM 89.9 0.73 
IgG 95.3 0.85 
Egens 100 IgM 92.0 0.82 
IgG 97.0 0.93 
Hightop 119 IgM 92.4 0.63 
IgG 97.5 0.94 
MultiG 100 IgM 99.0 0.95 
IgG 100 1.0 
Novita 150 IgM 97.3 0.79 
IgG 93.3 0.72 
Orient 
Gene 
150 IgM 95.3 0.89 
IgG 98.7 0.97 
Really 
Take 
100 IgM 96.0 0.92 
IgG 97.0 0.94 
Shanghai 
Liangrun 
119 IgM 99.2 0.0 
IgG 97.5 0.95 
Sino 
Care 
100 IgM NA 
IgG NA 
IgM/IgG 98.0 0.95 
Standard 
Q 
100 IgM 99.0 0.98 
IgG 100 1.0 
Tigsun 150 IgM 90.7 0.78 
IgG 94.0 0.87 
Vazyme 100 IgM 97.0 0.90 
IgG 99.0 0.98 
VivaDiag 150 IgM 98.0 0.95 
IgG 100 1.0 
Wiz 
Biotech 
150 IgM 99.3 0.66 
IgG 99.3 0.66 
Wondfo 100 IgM/IgG 98.0 0.96 
Zybio 100 IgM 91.0 0.82 
















All of the test kits recommended above for IgG (Boston, Multi G, 
tandard Q, and VivaDiag) had almost perfect agreement; similarly 
or either IgG or IgM (IgG/IgM), MultiG and Standard Q had almost 
erfect agreement, while Autobio had substantial agreement. 
To evaluate the performance of the 25 RDTs, a well- 
haracterized reference panel of plasma specimens from SARS- 
oV-2 qRT-PCR-positive individuals that had been screened by 
eans of six SARS-CoV-2 ELISA/CMIA IgM and IgG assays was used. 
his approach is different from many other studies that have used 285 ny samples from qRT-PCR-positive individuals. The reason for this 
pproach is that not all qRT-PCR-positive individuals have antibod- 
es; the presence of antibodies depends on the time since infection, 
he severity of infection, and a number of other factors. A further 
tep to increase the relevance of the reference panel was to include 
LISA/CMIA kits that targeted either the nucleocapsid or the spike 
ntigen where possible. 
There are other published evaluation reports that have similarly 
hown poor serological RDT performance compared to that re- 
























































































orted by the manufacturer ( Deeks et al., 2020 ; Jacobs et al., 2020 ;
auloup-Fellous et al., 2021 ). Since some of these other studies 
sed samples from any qRT-PCR-positive individuals, they showed 
ower sensitivity in the first week post symptom onset, with im- 
roved performance at later time points. Few studies have evalu- 
ted RDTs using samples taken beyond 1 month post symptom on- 
et. Furthermore, there is limited information on the performance 
f these RDTs in asymptomatic participants ( Deeks et al., 2020 ). 
While a serial or orthogonal ( Xu et al., 2020 ) testing approach 
as been recommended for surveillance especially when using 
LISAs ( CDC, 2020b ), here we propose that parallel testing with 
DTs could also be a viable approach. With this approach, two 
DTs with ≥98% sensitivity and specificity could be used together 
ith an equally accurate RDT as a tie-breaker for discrepant re- 
ults. 
This study evaluated only 25 RDTs, but we are aware that many 
ARS-CoV-2 RDT kits are on market. With the well characterized 
anel of samples we now have and with WHO serological reference 
tandards now available from the National Institute for Biological 
tandards and Control (NIBSC), the validation of additional RDTs 
ill be quicker. 
The study had some limitations. The selection of the RDTs to 
valuate was dictated by what was provided to us by the local dis- 
ributors in the country. Some distributors provided test kits for 
valuation, less than the desired 150 samples. Another limitation 
as that it was not possible to procure an IgM ELISA based on 
he nucleocapsid protein. Some of the ELISA kits procured did not 
erform well and hence the results with these kits were excluded 
rom the development of the serological reference panel. Subse- 
uent to the completion of this evaluation, it was discovered that 
uthorization for the use of some of the RDTs had been revoked; 
hey were removed from the FDA EUA notification list as of Febru- 
ry 23, 2021. 
In conclusion, using a reference panel of well characterized 
lasma samples and considering the sensitivity and specificity of 
ombined IgG and IgM results, and inter-reader agreement, this 
valuation found that three RDTs performed well: Autobio, MultiG, 
nd Standard Q. Where only the IgG result is of interest, there were 
our RDTs that performed well: Boson, MultiG, Standard Q, and Vi- 
aDiag. 
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